Trial Profile
Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Pentostatin (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 28 Aug 2020 Status changed from discontinued to withdrawn prior to enrolment.
- 31 Oct 2011 New trial record